| 1 |
32869328 | An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes. | 2021 Feb |
1 |
| 2 |
33540768 | Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals. | 2021 Feb 2 |
1 |
| 3 |
34429480 | Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. | 2021 Aug 24 |
1 |
| 4 |
32272615 | Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. | 2020 Apr 7 |
1 |
| 5 |
32406758 | Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions. | 2020 May |
1 |
| 6 |
32863324 | Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide. | 2020 Sep 8 |
4 |
| 7 |
30992242 | Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. | 2019 Jun |
1 |
| 8 |
31239454 | Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective. | 2019 Jun 25 |
1 |
| 9 |
28992765 | Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study. | 2018 Sep |
1 |
| 10 |
29119333 | Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. | 2018 Jun |
7 |
| 11 |
29326367 | Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug. | 2018 Mar |
5 |
| 12 |
28435143 | Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans. | 2017 Sep |
3 |
| 13 |
26886310 | The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism. | 2016 Mar |
2 |
| 14 |
28057172 | Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8. | 2016 Oct - Dec |
3 |
| 15 |
25758259 | Piezotronic-effect enhanced drug metabolism and sensing on a single ZnO nanowire surface with the presence of human cytochrome P450. | 2015 Mar 24 |
1 |
| 16 |
26255664 | Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. | 2015 |
1 |
| 17 |
24368832 | An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome P4502C9 in vivo activity. | 2014 Mar |
2 |
| 18 |
24730468 | The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. | 2014 Sep |
2 |
| 19 |
25075423 | Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient. | 2014 |
4 |
| 20 |
25202272 | In vitro and in vivo assessment of CYP2C9-mediated herb-herb interaction of Euphorbiae Pekinensis Radix and Glycyrrhizae Radix. | 2014 |
1 |
| 21 |
23380426 | Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. | 2013 Apr |
2 |
| 22 |
23727057 | Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism. | 2013 Jul 16 |
1 |
| 23 |
24521898 | [Identification of a novel CYP2C9 gene mutation (1400T>C) and assessment of its enzymatic activity in vitro]. | 2013 Nov 26 |
1 |
| 24 |
22311023 | Tolbutamide hydroxylation by hepatic microsomes from Atlantic salmon (Salmo salar L.). | 2012 Jun |
1 |
| 25 |
22547083 | Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. | 2012 Aug |
3 |
| 26 |
22886551 | Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2. | 2012 Sep |
4 |
| 27 |
21182487 | Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. | 2011 |
1 |
| 28 |
21365364 | In vitro determination of the effect of Andrographis paniculata extracts and andrographolide on human hepatic cytochrome P450 activities. | 2011 Jul |
1 |
| 29 |
21757329 | Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes. | 2011 Oct 15 |
1 |
| 30 |
19715737 | Polymorphisms of human cytochrome P450 2C9 and the functional relevance. | 2010 Dec 5 |
2 |
| 31 |
20609060 | Inhibition of human liver microsomal CYP by nateglinide. | 2010 May |
1 |
| 32 |
23964176 | Effects of some commonly used Saudi folk herbal medications on the metabolic activity of CYP2C9 in human liver microsomes. | 2010 Jul |
4 |
| 33 |
19245785 | Equine cytochrome P450 2C92: cDNA cloning, expression and initial characterization. | 2009 May 1 |
1 |
| 34 |
19369937 | Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. | 2009 Jul |
1 |
| 35 |
19515014 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. | 2009 |
1 |
| 36 |
19651758 | Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. | 2009 Oct |
1 |
| 37 |
19925388 | Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. | 2009 Sep |
2 |
| 38 |
17597710 | Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. | 2008 Feb |
4 |
| 39 |
18356043 | Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. | 2008 May |
2 |
| 40 |
18793590 | Cytochrome P450 2C9 mediated metabolism in people with and without cancer. | 2008 Jul |
1 |
| 41 |
19026171 | Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. | 2008 Dec |
1 |
| 42 |
17132763 | Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. | 2007 Feb |
1 |
| 43 |
16388406 | Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. | 2006 Mar |
1 |
| 44 |
16867169 | Inhibitory effects of cytostatically active 6-aminobenzo[c]phenanthridines on cytochrome P450 enzymes in human hepatic microsomes. | 2006 Jul |
1 |
| 45 |
17010942 | Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions. | 2006 Dec 15 |
3 |
| 46 |
15537834 | Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. | 2005 Feb |
1 |
| 47 |
15875171 | Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity. | 2005 Jun |
1 |
| 48 |
16141567 | Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. | 2005 Sep |
1 |
| 49 |
16268502 | [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray]. | 2005 Aug |
6 |
| 50 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
1 |